REG - Partners Grp Pvt Eqt Partners Grp E-PEYS - NAV increases by 0.5% in September

Partners Private EquityAnnouncement

04/11/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241104:nRSD7171Ka&default-theme=true

RNS Number : 7171K  Partners Group Private Equity Ltd  04 November 2024

(LSE: PEYS/PEY)

 

Partners Group Private Equity Limited

 

NAV increases by 0.5% in September

 

 

·    NAV increased by 0.5% to EUR 14.24 per share; total net assets at EUR
984.62 million

·    Positive value creation (0.9%) partially offset by adverse currency
movements (-0.3%)

·    KinderCare, the fifth largest portfolio company in PGPE Ltd, was the
largest contributor to the NAV increase following its IPO pricing

·    PGPE Ltd invested EUR 6.7 million and received distributions of EUR
6.3 million

 

In September, PGPE Ltd invested EUR 6.7 million, of which EUR 5.5 million was
in FairJourney Biologics, a leading European antibody discovery Contract
Research Organization (CRO) based in Porto, Portugal. Founded in 2012,
FairJourney provides services for the discovery, engineering, production, and
characterization of antibodies. FairJourney has worked with over 250 clients
across the globe to develop more than 4,000 unique screening libraries for
identifying antibodies. The company's partnerships with its customers have
yielded 14 therapies that are currently in active clinical development to
treat unmet patient needs across oncology, immunology, and cardiovascular
disease. FairJourney is set to benefit from structural market tailwinds,
including increased R&D spend, outsourcing trends, and a favorable
regulatory landscape. Partners Group will work with management on a value
creation plan for FairJourney that will expand its technology and capabilities
through organic and inorganic investment to unlock faster, more effective drug
development for its partners.

 

PGPE Ltd received distributions totaling EUR 6.3 million, with EUR 6.0 million
coming from the sale of a portion of its stake in Galderma, a pure-play
dermatology category leader. The shares were sold to L'Oréal, via an
off-market block trade that saw the French beauty and cosmetics group invest
for a 10% stake in Galderma. The two companies have also agreed on a
scientific partnership to develop advanced, future-proof technologies with
direct applications in the field of dermatology.

 

 

Further information is available in the monthly report, which can be accessed
via:
https://www.partnersgroupprivateequitylimited.com/en/investor-relations/financial-reports/

 

 

Ends.

 

About Partners Group Private Equity Limited

PGPE Ltd (formerly Princess Private Equity Holding Limited) is an investment
holding company founded in 1999 and domiciled in Guernsey. It invests in
private equity direct investments. PGPE Ltd is managed in its investment
activities by Partners Group, a global private markets investment management
firm with USD 149 billion in investment programs under management in private
markets, of which USD 76 billion is in private equity. PGPE Ltd aims to
provide shareholders with long-term capital growth and an attractive dividend
yield. PGPE Ltd is traded on the Main Market of the London Stock Exchange
(ticker: PEY for the Euro Quote; PEYS for the Sterling Quote).

 

Contacts

Partners Group Private Equity Limited:

pgpe-ltd@partnersgroup.com

www.partnersgroupprivateequitylimited.com

 

 Investor relations contact:                  Media relations contact:

 Andreea Mateescu                             Jenny Blinch

 Phone: +41 41 784 66 73                      Phone: +41 41 784 65 26

 E-mail: andreea.mateescu@partnersgroup.com   E-mail: jenny.blinch@partnersgroup.com

 

Registered Number: 35241   LEI: 54930038LU8RDPFFVJ57

Notes:

1.     Note that references in this announcement to Partners Group Private
Equity Limited have been abbreviated to "PGPE Ltd" or "Company". References to
Partners Group AG have been abbreviated to "Partners Group" or "Investment
Manager".

2.     This document does not constitute an offer to sell or a
solicitation of an offer to buy or subscribe for any securities and neither is
it intended to be an investment advertisement or sales instrument of Partners
Group Private Equity Limited. The distribution of this document may be
restricted by law in certain jurisdictions. Persons into whose possession this
document comes must inform themselves about and observe any such restrictions
on the distribution of this document. In particular, this document and the
information contained therein is not for distribution or publication, neither
directly nor indirectly, in or into the United States of America, Canada,
Australia or Japan.

3.     This document may have been prepared using financial information
contained in the books and records of the product described herein as of the
reporting date. This information is believed to be accurate but has not been
audited by any third party. This document may describe past performance, which
may not be indicative of future results. No liability is accepted for any
actions taken on the basis of the information provided in this document.
Neither the contents of PGPE Ltd' website nor the contents of any website
accessible from hyperlinks on PGPE Ltd' website (or any other website) is
incorporated into, or forms part of, this announcement.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCXXLFBZFLZFBX